Home › Funds › Cormorant Asset Management, LP › SYRE

Cormorant Asset Management, LP position in SYRE

SPYRE THERAPEUTICS INC · Health Care

Cormorant Asset Management, LP reported holding 125,000 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.1M, representing 0.80% of its reported portfolio and ranking #34 among its reported holdings. Cormorant Asset Management, LP has disclosed SYRE holdings in 4 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)125.00K sh
Reported value held$11.13M
Portfolio Weight0.80%
First reportedQ4 2023
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's SYRE position evolved

Cormorant Asset Management, LP first disclosed a stake in SYRE in Q4 2023 at 937,080 shares (US$20.2M). Across 4 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 125,000 shares valued at US$11.1M — a reduction of -100,000 shares quarter over quarter.. Notable position changes include a 73% trim in Q1 2024, a 44% trim in Q3 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 937.08K $20.17M New
Q1 2024 250.00K $9.48M Reduce
Q2 2026 225.00K $19.98M New
Q3 2026 125.00K $11.13M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has Cormorant Asset Management, LP held SYRE?

Cormorant Asset Management, LP has disclosed SYRE holdings in 4 of the last 12 reported quarters, going back to Q4 2023.

What is Cormorant Asset Management, LP's current position in SYRE?

As of Q3 2026, Cormorant Asset Management, LP holds 125.00K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $11.13M, representing 0.80% of its reported portfolio and ranking #34.

Has Cormorant Asset Management, LP been buying or selling SYRE?

In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP reduced its position in SYRE.

Which other funds hold SYRE?

Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 69 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.